Reactions 1882, p317 - 20 Nov 2021

mRNA-1273

Nephrotic syndrome secondary to minimal change disease: case report

A 43-year-old man developed nephrotic syndrome secondary to minimal change disease secondary to mRNA-1273 vaccine. The man presented with progressive bilateral lower limb oedema since 2 weeks. He had no significant medical history. He reported that, he developed symptoms 7 days after receiving first dose of mRNA-1273 [Moderna COVID-19 vaccine; dosage and route not stated] vaccine. Following 10–14 days, he developed scrotal swelling and dyspnea. His physical examination revealed significant bilateral lower limb pitting edema extending to above the knees, decreased air entry at lung bases and scrotal swelling. His laboratory investigations revealed BP 150/92mm Hg, hypoalbuminaemia, hyperlipidaemia and proteinuria. Later, renal biopsy showed minimal change disease with IgA nephropathy which was considered to be secondary to mRNA-1273 vaccine.

The man was treated with prednisolone and furosemide. Thereafter, his serum albumin levels doubled, oedema resolved and proteinuria decreased within one week of treatment.

Thappy SB, et al. Nephrotic syndrome secondary to minimal change disease following moderna COVID-19 vaccine. Journal of the American Society of Nephrology 32: 523, Jan 2021. Available from: URL: http://doi.org/10.1681/asn.2020121802 [abstract]